UPDATE: Cytosorbents (CTSO) Tops Q2 EPS View
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- S&P 500, Nasdaq fall as investors juggle earnings, Mideast risks and tariffs
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil retreats from above $100, still set for weekly rise on Middle East escalation
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Meta’s new seller app hits eBay where it hurts most
CytoSorbents Reports Steady Growth in Q2 2015
August 13, 2015 4:15 PM EDTMONMOUTH JUNCTION, N.J., Aug. 13, 2015 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to reduce deadly uncontrolled inflammation in hospitalized patients around the world, reported financial and operational results for the three and six months ended June 30, 2015.
Highlights Potential Catalysts for Accelerated Growth in the Second Half of 2015
Recent Financial Highlights:
Product revenues for the second quarter of... More